<unk>  is a interleukin-23 antagonist that is FDA approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.   Common adverse reactions include upper respiratory infections, injection site reactions, and diarrhea.
Tildrakizumab
Risankizumab
Mogamulizumab
Motavizumab
Caplacizumab
Ixekizumab
Idarucizumab
Tocilizumab